Asset Details
Do you wish to reserve the book?
Zinc oxide resveratrol nanoparticles ameliorate levofloxacin-induced hepatotoxicity in rat model
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Zinc oxide resveratrol nanoparticles ameliorate levofloxacin-induced hepatotoxicity in rat model
Do you wish to request the book?
Zinc oxide resveratrol nanoparticles ameliorate levofloxacin-induced hepatotoxicity in rat model
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Zinc oxide resveratrol nanoparticles ameliorate levofloxacin-induced hepatotoxicity in rat model
2025
Overview
Background
The present investigation assessed the potential ameliorating effect of zinc oxide resveratrol nanoparticles against Levofloxacin-induced liver damage in rats.
Methods
Fifty adult Wistar rats were split up into five groups at random. (
n
= 10). GI, (control): was orally gavaged with distilled water; G II (LFX): was orally given levofloxacin (LFX) (40 mg/kg BW). G III was orally administered zinc oxide resveratrol nanoparticles (Zn- RSV) (20 mg/kg BW). G IV: was given Zn-RSV as GIII and LFX as GII simultaneously (LFX + Zn-RSV). GV: was given LFX as GII and zinc oxide (20 mg/kg BW) (LFX + Zn). All treatments were given every other day for two months.
Results
Administration of zinc oxide resveratrol nanoparticles (Zn-RSV NPs) significantly mitigated levofloxacin (LFX)-induced hepatotoxicity in rats. Compared to LFX-treated groups through improved liver function via lowered serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea, and creatinine levels. Also, reduced oxidative stress markers, decreased malondialdehyde (MDA) and nitric oxide (NO) levels in hepatic tissue and enhanced antioxidant defenses, increased superoxide dismutase (SOD) and catalase activities, restoring them to near-normal levels. Modulated apoptosis: Downregulated pro-apoptotic BAX expression and upregulated anti-apoptotic Bcl-2 expression, promoting cell survival. Zn-RSV NPs alleviated histopathological changes through mitigated LFX-induced degenerative and necrotic changes in hepatic tissue, preserving tissue architecture.
Conclusions
This study revealed that zinc oxide resveratrol nanoparticles modulated levofloxacin-induced hepatic damage by lowering inflammation and oxidative stress while increasing the activity of antioxidant enzymes in rat hepatic tissue.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Animals
/ Anti-Bacterial Agents - toxicity
/ Antioxidants - administration & dosage
/ Aspartate Aminotransferases - blood
/ Biomedical and Life Sciences
/ Chemical and Drug Induced Liver Injury - drug therapy
/ Chemical and Drug Induced Liver Injury - metabolism
/ Chemical and Drug Induced Liver Injury - pathology
/ Liver
/ Male
/ Nanoparticles - administration & dosage
/ Oxidative Stress - drug effects
/ Rats
/ Resveratrol - administration & dosage
/ Urea
/ Zinc Oxide - administration & dosage
